Credo Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 15.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 13.50 Cr
as on 24-10-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 27.39 Cr
as on 24-10-2024
- Revenue 10.36%
(FY 2023)
- Profit -17.83%
(FY 2023)
- Ebitda -5.70%
(FY 2023)
- Net Worth 22.97%
(FY 2023)
- Total Assets -2.77%
(FY 2023)
About Credo Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 15.50 Cr and a paid-up capital of Rs 13.50 Cr.
The company currently has active open charges totaling ₹27.39 Cr.
Siva Aluru, Aluru Krishna, and Kandru Madhavarao serve as directors at the Company.
- CIN/LLPIN
U24232TG2014PTC112849
- Company No.
112849
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Credo Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siva Aluru  | Managing Director | 03-Jul-2014 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Aluru Krishna | Director | 03-Jul-2014 | Current |
| Kandru Madhavarao | Director | 01-Apr-2015 | Current |
Financial Performance of Credo Life Sciences.
Credo Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.36% increase. The company also saw a substantial fall in profitability, with a 17.83% decrease in profit. The company's net worth Soared by an impressive increase of 22.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Credo Life Sciences?
In 2023, Credo Life Sciences had a promoter holding of 84.17% and a public holding of 15.83%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Credo Pharma Private LimitedActive 11 years 5 monthsSiva Aluru, Aluru Krishna and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 03 Jan 2023 | ₹3.50 M | Open |
Indian Bank Creation Date: 31 Oct 2016 | ₹27.04 Cr | Open |
How Many Employees Work at Credo Life Sciences?
Credo Life Sciences has a workforce of 177 employees as of May 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Credo Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Credo Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
